Personalized, targeted treatment approaches that harness the body's own immune cells to fight cancer.
Explore Treatment PlatformsCell therapy is a next-generation treatment approach that uses the patient's own immune cells or donor-derived cells to combat disease — particularly cancer. Unlike conventional chemotherapy and radiation, it destroys only target cells without harming healthy tissue.
The CAR-T era began with Kymriah's FDA approval in 2017 and has since expanded to six products: Kymriah, Yescarta, Tecartus, Breyanzi, Abecma, and Carvykti. These products are used in the treatment of B-ALL, large B-cell lymphoma, mantle cell lymphoma, and multiple myeloma. By late 2024, solid tumor cell therapies such as AMTAGVI (melanoma) and TECELRA (synovial sarcoma) further broadened the field.
Cell therapy is no longer experimental — it is a regulatory-approved, evidence-based treatment standard.
CAR-T cell therapy response rates vary by cancer type. The ELIANA trial reported 81% complete remission in pediatric B-ALL (Maude et al., NEJM 2018), while the ZUMA-1 trial demonstrated 83% overall response and 58% complete response in refractory large B-cell lymphoma (Neelapu et al., NEJM 2017). At five-year follow-up, 42.6% of patients maintained survival.
These rates demonstrate that cell therapy is a life-saving option in refractory cases where conventional chemotherapy and radiation have failed.
The global cell therapy market is valued at $7-18 billion in 2025 according to various research firms. The market is expected to exceed $47 billion by 2034 with an annual growth rate of over 20%. Growth is driven by expanding CAR-T indications, declining manufacturing costs, and increasing access in emerging markets.
Genkord Therapeutics holds a strategic position in this rapidly growing global market with domestic cGMP-compliant manufacturing in Turkey.
Genkord Therapeutics manufactures three ministry-approved cellular therapy platforms in its own cGMP-certified laboratory.
Natural Killer Cell
The elite warriors of innate immunity. Capable of recognizing and destroying tumor cells instantly without prior sensitization. A safe treatment option with a favorable side-effect profile.
Cytokine-Induced Killer Cell
Cytokine-activated killer cells combining NK and T cell properties. Their hybrid phenotype enables broad-spectrum anti-tumor activity with MHC-unrestricted target recognition.
Dendritic Cell
The "teacher" cells of the immune system. They process and present tumor antigens to T cells, triggering a potent, targeted immune response. The foundation of personalized cancer vaccine approaches.
Operating in cell biology since 2003, Genkord develops and manufactures ministry-approved cellular immunotherapy products in its own cGMP-certified R&D facility.
All processes from cell isolation to final product are carried out under one roof in our cGMP-certified R&D facility.
Over 20 years of cell biology expertise. More than 15 biological products successfully developed and commercialized.
NK cell, CIK, and Dendritic Cell — three distinct ministry-approved cellular therapy platforms actively in production.
Get in touch with our team for R&D collaborations, clinical study partnerships, or product information.
